Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo

20253 citationsJournal Articlehybrid Open Access

Authors

Guillaume Ravel · AstraZeneca (France)

Xavier Gaume · AstraZeneca (France)

Corentin Berardet · AstraZeneca (France)

Clémentine Chalmey · AstraZeneca (France)

Haruaki Kurasaki · Peptidream (Japan)

Tatsuya Tomiyama · Peptidream (Japan)

Patrick Reid ·

Abstract

These results support the investigation of ALXN2420 as a combination therapy for the treatment of patients with acromegaly inadequately controlled by SSAs.

Topics & Keywords

Pituitary Gland Disorders and Treatments Growth Hormone and Insulin-like Growth Factors Neuroendocrine Tumor Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Endocrinology

Volume 192, Issue 3, pp. 299-307

DOI: 10.1093/ejendo/lvaf043

Field-Weighted Citation Impact: 4.29